Black Diamond Therapeutics, Inc. Profile Avatar - Palmy Investing

Black Diamond Therapeutics, Inc.

Black Diamond Therapeutics, Inc., a biotechnology company, discover, develops, and commercializes medicines for patient with genetically defined tumors. It develops BDTX-189, an irreversible small molecule inhibitor that is designed to targets oncogenic …

Biotechnology
US, Cambridge [HQ]
Revenue Breakdowns

Segment Analysis Beta

The financial segments are sourced from the SEC' 10-K statement.

Revenue By Top Segments

Black Diamond Therapeutics, Inc. can't present it's sankey chart.

Historical Revenue By Segment

Last 3Y, in million USD

Black Diamond Therapeutics, Inc. can't present revenue by segment

End of BDTX's Analysis
CIK: 1701541 CUSIP: 09203E105 ISIN: US09203E1055 LEI: - UEI: -
Secondary Listings
BDTX has no secondary listings inside our databases.